# Nabriva Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nabriva-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Vienna, Austria
- Website: www.nabriva.com
- Total disclosed funding: $218M
- Latest round: Series B (Apr 7, 2015)
- Investors on record: 10

## About

Nabriva Therapeutics GmbH is a pharmaceutical company focused on developing innovative antibiotics for serious infections caused by antibiotic-resistant bacteria, addressing critical healthcare needs worldwide.Founded in 2006 and headquartered in Vienna, Austria, Nabriva Therapeutics GmbH specializes in antibiotic development. The company has successfully raised USD 15.00 mn through a Private Placement/Follow on round in December 2020, bringing its total amount raised to USD 15.00 mn. Nabriva has completed a total of 9 deals, with the most recent deal dated September 18, 2015. The company was founded by a team of individuals with a shared vision for antibiotic innovation.Nabriva Therapeutics focuses on the development of innovative therapeutic solutions for serious infections caused by antibiotic-resistant bacteria. Their core product offerings include a portfolio of antibiotics, with flagship products designed to treat acute bacterial skin and skin structure infections, as well as community-acquired bacterial pneumonia. These products utilize advanced compounds, such as lefamulin, which acts by inhibiting bacterial protein synthesis. Nabriva aims to address the critical need for effective treatments in an era where antibiotic resistance is a growing concern among healthcare providers and patients alike. The company serves a diverse customer base that includes hospitals, outpatient clinics, and specialized healthcare providers primarily in the United States and Europe, where the demand for novel antibiotics is significant.Nabriva Therapeutics generated USD 28.90 mn in revenue for the year 2021. The company operates on a B2B model, selling its antibiotic products directly to healthcare institutions and pharmacies. The pricing structure of its products is influenced by market demand and the unique therapeutic value they offer. Nabriva's flagship product, lefamulin, significantly contributes to its revenue, with pricing strategies that reflect its formulation and the pressing need for effective treatment options against resistant infections. The company continues to explore partnerships with other pharmaceutical entities to enhance distribution and expand market reach within its targeted geographical regions.Nabriva Therapeutics is actively working on expanding its portfolio of innovative antibiotics, with plans to develop and launch new products addressing antibiotic-resistant infections in the coming years. The company aims to enter new markets in Asia and Latin America by 2024, driven by increasing demand for effective antibiotics. The recent funding of USD 15.00 mn will be utilized to support research and development initiatives, enhance marketing strategies, and facilitate expansion into these emerging markets.

## Funding rounds

- Series B, Apr 7, 2015, $120M — OrbiMed Advisors, Wellcome Trust, Global Life Science Ventures, HBM Partners, Novartis Venture Fund, Vivo Capital, Phase4 Partners, Tavistock Group, EcoR1 Capital, Boxer Capital
- Series B, Jan 17, 2010, $22M — Wellcome Trust, Global Life Science Ventures, HBM Partners, Novartis Venture Fund, Phase4 Partners
- Series B, Oct 28, 2009, $22M — Wellcome Trust, Global Life Science Ventures, HBM Partners, Novartis Venture Fund, Phase4 Partners
- Series A, Jun 1, 2006, $54M — Wellcome Trust, Global Life Science Ventures, HBM Partners, Novartis Venture Fund, Phase4 Partners

## Investors

- Wellcome Trust — Series A, Series B
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B